Pfizer Inc (PFE)

$25.65 -0.24 (-0.93%)
Market Cap 145.84B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 8.09
Forward PE 8.74
Profit Margin 12.62%
Debt to Equity Ratio 0.66
Volume 59,470,500
Avg Vol 60,520,750
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 66%
Beta 0.47
Analysts Sell
Price Target $27.95

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Makingmillions192
Makingmillions192 Jan. 18 at 3:57 AM
$LEXX Don’t forget what happened last time we were here and started promo on CNBC 👀 This time we have phase 1b under our belt with a pending MTA deal in the works and multiple other pharma companies talking with us. 2026 has the makings to be a massive year here!! Buy and hold like the big boys are doing!! 💰 $NVO $PFE $LLY
1 · Reply
AstroGleam
AstroGleam Jan. 18 at 3:21 AM
”@CoralSharkie just had an absolutely unreal year. Straight next-level🌟 If you’re not following yet, fix that!! $CLOV $INTC $PFE $FBIO also watchingg
0 · Reply
Simonpoiree
Simonpoiree Jan. 18 at 12:45 AM
$CRML $MRNA $PFE
1 · Reply
Micheal_Pothead
Micheal_Pothead Jan. 17 at 11:14 PM
$PFE insane how long we have been grinding this line
0 · Reply
mountingmoney
mountingmoney Jan. 17 at 11:14 PM
$CRML I figuratively rollout the red carpet to any and all naysayers. I'm telling you this is going over $1,000. Who remembers what happened to $MRNA and $PFE? Government backing, increasingly critical importance and sustainable expansive growth of operations. You could also treat this as a debasement trade. Who buys gold? The United States "prints the money" for whatever they want. They trade effectively Monopoly money for tangible things.
0 · Reply
DailyAnalysis
DailyAnalysis Jan. 17 at 6:57 PM
$PFE is screaming accumulation. RSI reset to 55 while price defends the 50/200 EMA Golden Cross. Volume is running 2x average—smart money is absorbing the dip. The algos are primed for a violent move up. Do not fade this setup. @DailyAnalysis
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 17 at 4:20 PM
Enter: $PFE Calls Strike Price: $26 Expiry Date: FEB 06 2026 Buy in Price: $0.33 - $0.34 Sell Price: $0.57 Profit : +72% (Turn every $1 into $1.72) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
1 · Reply
taxplanr
taxplanr Jan. 17 at 4:19 PM
Public health notice for COVID jab participants $BNTX $MRNA $PFE https://www.tiktok.com/t/ZThh6a6t3/
0 · Reply
umiak1
umiak1 Jan. 17 at 3:38 PM
$PFE “investors are wary of stocks with 5%-plus yields because of concerns about dividend security. Payout ratios are helpful in gauging safety. Investors want to see dividends at a lower percentage of earnings -- generally no more than 75%. And when dividends exceed earnings, it's a red flag about sustainability. A complementary approach favored by longtime dividend investor David King, co-manager of the Columbia Flexible Capital Income fund, is to compare dividend yields to the bond yields of the same company. If the dividend yield exceeds the bond yield, it's a sign that bond investors are comfortable with a company's creditworthiness and that the dividend is relatively safe. King says this works for companies with investment-grade bond ratings. He uses the 10-year corporate bond yield.”
1 · Reply
Paper_Route_Frank
Paper_Route_Frank Jan. 17 at 2:27 PM
$PFE Leap calls here. Personally passing for better opportunities.
0 · Reply
Latest News on PFE
Pfizer: Rebound Has Just Started

Jan 16, 2026, 1:08 PM EST - 1 day ago

Pfizer: Rebound Has Just Started

Pfizer: The Most Intriguing Value Play Of 2026

Jan 15, 2026, 8:58 AM EST - 2 days ago

Pfizer: The Most Intriguing Value Play Of 2026

Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Jan 13, 2026, 6:11 AM EST - 4 days ago

Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra

Jan 12, 2026, 6:43 PM EST - 5 days ago

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:16 PM EST - 5 days ago

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Jan 10, 2026, 10:00 AM EST - 7 days ago

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 8 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN AZN BMY LLY MRK NVO

Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

Jan 8, 2026, 8:00 AM EST - 9 days ago

Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

Jan 7, 2026, 2:16 PM EST - 10 days ago

Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

Quant Q&A With Steven Cress

Jan 7, 2026, 7:00 AM EST - 10 days ago

Quant Q&A With Steven Cress

CLS CRDO ET FIX MRK

America's new vaccine doctrine for children replaces data with dogma

Jan 6, 2026, 11:55 AM EST - 11 days ago

America's new vaccine doctrine for children replaces data with dogma

MRNA

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

Jan 6, 2026, 7:30 AM EST - 11 days ago

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Jan 5, 2026, 10:00 AM EST - 12 days ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer 2026: The Reset Year

Jan 2, 2026, 2:52 PM EST - 15 days ago

Pfizer 2026: The Reset Year

3 ultra-high-yield stocks to consider for $300 of dividend income in 2026

Dec 31, 2025, 8:37 AM EST - 17 days ago

3 ultra-high-yield stocks to consider for $300 of dividend income in 2026

AGNC PFLT

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

Dec 31, 2025, 6:08 AM EST - 17 days ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

GSK LLY NVS SNY

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

Dec 26, 2025, 10:35 PM EST - 22 days ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM ABT AMGN AVGO BCPC

Pfizer says patient dies after receiving hemophilia drug in trial

Dec 23, 2025, 11:24 AM EST - 25 days ago

Pfizer says patient dies after receiving hemophilia drug in trial

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Dec 19, 2025, 11:45 AM EST - 4 weeks ago

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 4 weeks ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY GILD LLY MRK

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Dec 18, 2025, 10:00 AM EST - 4 weeks ago

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

Dec 18, 2025, 6:58 AM EST - 4 weeks ago

Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 4 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN AZN BMY LLY NVS

Pfizer Stock Can Sink More. Here Is How

Dec 17, 2025, 2:36 PM EST - 4 weeks ago

Pfizer Stock Can Sink More. Here Is How

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

Dec 17, 2025, 10:14 AM EST - 4 weeks ago

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

MRK

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Dec 17, 2025, 6:45 AM EST - 4 weeks ago

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Dec 16, 2025, 2:39 PM EST - 4 weeks ago

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Pfizer falls on disappointing guidance

Dec 16, 2025, 12:33 PM EST - 4 weeks ago

Pfizer falls on disappointing guidance

Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Dec 16, 2025, 10:12 AM EST - 4 weeks ago

Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Here's why Pfizer is revising its revenue forecasts

Dec 16, 2025, 7:47 AM EST - 4 weeks ago

Here's why Pfizer is revising its revenue forecasts

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Dec 16, 2025, 7:25 AM EST - 4 weeks ago

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings

Dec 16, 2025, 7:16 AM EST - 4 weeks ago

Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings

Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Dec 16, 2025, 6:54 AM EST - 4 weeks ago

Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

Dec 16, 2025, 6:45 AM EST - 4 weeks ago

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

Dec 15, 2025, 8:24 AM EST - 4 weeks ago

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

ADPT

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Dec 15, 2025, 8:00 AM EST - 4 weeks ago

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

ADPT

Pfizer Declares First-Quarter 2026 Dividend

Dec 12, 2025, 12:00 PM EST - 5 weeks ago

Pfizer Declares First-Quarter 2026 Dividend

Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends

Dec 12, 2025, 8:45 AM EST - 5 weeks ago

Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends

AMLP MO MSTY OHI

Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial

Dec 12, 2025, 7:24 AM EST - 5 weeks ago

Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial

Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

Dec 10, 2025, 11:38 AM EST - 5 weeks ago

Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Dec 10, 2025, 8:15 AM EST - 5 weeks ago

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?

Dec 9, 2025, 3:30 PM EST - 5 weeks ago

Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

Dec 9, 2025, 11:14 AM EST - 5 weeks ago

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons

Dec 9, 2025, 10:59 AM EST - 5 weeks ago

Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons

Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains

Dec 9, 2025, 10:45 AM EST - 5 weeks ago

Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains

Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500

Dec 9, 2025, 10:15 AM EST - 5 weeks ago

Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500

AES AMCR ARE CAG CPB D DOC

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Dec 9, 2025, 6:55 AM EST - 5 weeks ago

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Pfizer partners with YaoPharma for weight management treatment

Dec 9, 2025, 6:38 AM EST - 5 weeks ago

Pfizer partners with YaoPharma for weight management treatment

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

Dec 9, 2025, 6:30 AM EST - 5 weeks ago

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Dec 6, 2025, 5:15 PM EST - 6 weeks ago

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Makingmillions192
Makingmillions192 Jan. 18 at 3:57 AM
$LEXX Don’t forget what happened last time we were here and started promo on CNBC 👀 This time we have phase 1b under our belt with a pending MTA deal in the works and multiple other pharma companies talking with us. 2026 has the makings to be a massive year here!! Buy and hold like the big boys are doing!! 💰 $NVO $PFE $LLY
1 · Reply
AstroGleam
AstroGleam Jan. 18 at 3:21 AM
”@CoralSharkie just had an absolutely unreal year. Straight next-level🌟 If you’re not following yet, fix that!! $CLOV $INTC $PFE $FBIO also watchingg
0 · Reply
Simonpoiree
Simonpoiree Jan. 18 at 12:45 AM
$CRML $MRNA $PFE
1 · Reply
Micheal_Pothead
Micheal_Pothead Jan. 17 at 11:14 PM
$PFE insane how long we have been grinding this line
0 · Reply
mountingmoney
mountingmoney Jan. 17 at 11:14 PM
$CRML I figuratively rollout the red carpet to any and all naysayers. I'm telling you this is going over $1,000. Who remembers what happened to $MRNA and $PFE? Government backing, increasingly critical importance and sustainable expansive growth of operations. You could also treat this as a debasement trade. Who buys gold? The United States "prints the money" for whatever they want. They trade effectively Monopoly money for tangible things.
0 · Reply
DailyAnalysis
DailyAnalysis Jan. 17 at 6:57 PM
$PFE is screaming accumulation. RSI reset to 55 while price defends the 50/200 EMA Golden Cross. Volume is running 2x average—smart money is absorbing the dip. The algos are primed for a violent move up. Do not fade this setup. @DailyAnalysis
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 17 at 4:20 PM
Enter: $PFE Calls Strike Price: $26 Expiry Date: FEB 06 2026 Buy in Price: $0.33 - $0.34 Sell Price: $0.57 Profit : +72% (Turn every $1 into $1.72) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
1 · Reply
taxplanr
taxplanr Jan. 17 at 4:19 PM
Public health notice for COVID jab participants $BNTX $MRNA $PFE https://www.tiktok.com/t/ZThh6a6t3/
0 · Reply
umiak1
umiak1 Jan. 17 at 3:38 PM
$PFE “investors are wary of stocks with 5%-plus yields because of concerns about dividend security. Payout ratios are helpful in gauging safety. Investors want to see dividends at a lower percentage of earnings -- generally no more than 75%. And when dividends exceed earnings, it's a red flag about sustainability. A complementary approach favored by longtime dividend investor David King, co-manager of the Columbia Flexible Capital Income fund, is to compare dividend yields to the bond yields of the same company. If the dividend yield exceeds the bond yield, it's a sign that bond investors are comfortable with a company's creditworthiness and that the dividend is relatively safe. King says this works for companies with investment-grade bond ratings. He uses the 10-year corporate bond yield.”
1 · Reply
Paper_Route_Frank
Paper_Route_Frank Jan. 17 at 2:27 PM
$PFE Leap calls here. Personally passing for better opportunities.
0 · Reply
picturepainter
picturepainter Jan. 17 at 1:31 PM
$PFE the year is 2050 and the price of Pfizer is 25.35 🤦🏼‍♂️
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Jan. 17 at 11:17 AM
$PFE Not a high-growth story, but long-term looks appealing. Price is at the lower bound of the uptrend channel, with volume quietly accumulating. Technicals suggest it could be trying to form a bottom here — patience may pay off. If this helps, tap @QuantitativeTrading_
0 · Reply
TalkMarkets
TalkMarkets Jan. 17 at 8:18 AM
Top Picks 2026: Pfizer Inc. $PFE https://talkmarkets.com/content/stocks--equities/top-picks-2026-pfizer-inc?post=550747
0 · Reply
Willieberich
Willieberich Jan. 17 at 12:59 AM
$PFE looks like an uptrend to me since April 11th .the best part is look at that huge green candle on the left. That was never violated .I says it's going to 27...
1 · Reply
TheWinningStock
TheWinningStock Jan. 16 at 10:55 PM
$CRDL <<---another winner...🤑 https://www.barchart.com/story/news/37082631/cardiol-therapeutics-announces-bought-deal-financing-for-gross-proceeds-of-13-5-million.. $PFE $IBRX ..
0 · Reply
DragonAlgo
DragonAlgo Jan. 16 at 9:15 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-01-16 | Strike: $25.00 | Type: CALL Option Plan (premium): Entry: $0.69 Stop: $0.49 TP1: $0.89 TP2: $1.16 TP3: $1.64 🔗 https://dragonalgo.com
0 · Reply
Micheal_Pothead
Micheal_Pothead Jan. 16 at 9:01 PM
$PFE insane volume during the 1 minute after close
0 · Reply
Micheal_Pothead
Micheal_Pothead Jan. 16 at 8:31 PM
$PFE idk why I thought we would see 26 today
1 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Jan. 16 at 8:06 PM
$PFE maybe Bourla should do less talking and BUY more shares to show confidence and conviction on outlook. Look what happened to Micron after insider buying even at lofty levels.... know that Bourla has good bit of shares, but he also has a fat paycheck and needs to jump on the table with energy
1 · Reply
Micheal_Pothead
Micheal_Pothead Jan. 16 at 8:01 PM
$PFE manipulated POS 🥰
0 · Reply
Micheal_Pothead
Micheal_Pothead Jan. 16 at 7:57 PM
$PFE lol…
0 · Reply
Kgra
Kgra Jan. 16 at 7:44 PM
$PFE crawling back to even then 26 lfg
0 · Reply